Dumas G, (, 2016), Blood, (Link to abstract)
The authors analyzed the effect of eculizumab, an anti-C5 monoclonal antibody, on three patients with Sickle Cell Disease (SCD) affected with delayed hemolytic transfusion reaction (DHTR) after blood transfusions. Administration of 2 doses of eculizumab led to reduction of hemolysis and vasculopathy. Despite normal C3 levels, there were signs of terminal complement activation in these patients providing a basis of the mechanisms implicated.
* Eculizumab showed efficacy on delayed hemolytic transfusion reactions in three SCD-patients and can be considered in severe cases.